These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 3471977)
1. [Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma]. Takagi T; Oguro M; Sakai C Rinsho Ketsueki; 1986 Dec; 27(12):2249-53. PubMed ID: 3471977 [No Abstract] [Full Text] [Related]
2. [Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma]. Hoshino S; Saito H; Wada M; Akutsu M; Shiozaki H; Takanashi M; Takei Y; Tanaka S; Teramura M; Takada K Rinsho Ketsueki; 1987 Mar; 28(3):358-65. PubMed ID: 3475485 [No Abstract] [Full Text] [Related]
3. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment. Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497 [TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy of multiple myeloma]. Uzuka Y; Saito Y; Ito T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944 [TBL] [Abstract][Full Text] [Related]
5. [Assessment of a nitrosurea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma (author's transl)]. Bezares R; Bomchil G; Saslavsky J; Pavlovsky S; Curutchet M; Quiroga Micheo E; Macchi A; Musso A; Suárez A; Pizzolato M Sangre (Barc); 1979; 24(3):241-51. PubMed ID: 472966 [No Abstract] [Full Text] [Related]
6. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)]. Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278 [No Abstract] [Full Text] [Related]
7. Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine. Ishii H Acta Med Okayama; 1988 Jun; 42(3):175-82. PubMed ID: 3165236 [TBL] [Abstract][Full Text] [Related]
8. [Four cases of therapy-related leukemia in multiple myeloma]. Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686 [TBL] [Abstract][Full Text] [Related]
9. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases]. Lila AM; Mazurov VI; Novik AA Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578 [No Abstract] [Full Text] [Related]
10. [Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern]. Kamiya O; Hoshino A; Ohara K; Nagata K; Ono Y; Saito M; Itou T; Yamamoto K Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):863-5. PubMed ID: 2469398 [No Abstract] [Full Text] [Related]
11. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)]. Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590 [No Abstract] [Full Text] [Related]
13. Alternating combination chemotherapy does not delay development of refractoriness in myeloma. Osby E; Beksac M; Reizenstein P Anticancer Res; 1986; 6(5):1145-7. PubMed ID: 3800322 [TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of multiple myeloma]. Golenkov AK Sov Med; 1991; (3):43-6. PubMed ID: 1882290 [No Abstract] [Full Text] [Related]
15. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma]. Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone]. Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486 [No Abstract] [Full Text] [Related]
17. [Polychemotherapy versus melphalan-prednisone in multiple myeloma]. Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590 [No Abstract] [Full Text] [Related]
18. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)]. Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017 [TBL] [Abstract][Full Text] [Related]
19. [Possibility of using interferon in the treatment of multiple myeloma]. Piatkowska-Jakubas B; Skotnicki AB; Blicharski J Przegl Lek; 1988; 45(10):747-50. PubMed ID: 3072590 [No Abstract] [Full Text] [Related]
20. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma. Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]